Leland Metheny | Case Comprehensive ...

Dr. Leland Metheny, MD

Claim this profile

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Studies Acute Lymphoblastic Leukemia
Studies Multiple Myeloma
12 reported clinical trials
23 drugs studied

Area of expertise

1

Acute Lymphoblastic Leukemia

Leland Metheny, MD has run 3 trials for Acute Lymphoblastic Leukemia. Some of their research focus areas include:

CD22 positive
Philadelphia chromosome positive
2

Multiple Myeloma

Leland Metheny, MD has run 3 trials for Multiple Myeloma. Some of their research focus areas include:

Stage I
Stage II

Affiliated Hospitals

Image of trial facility.

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Image of trial facility.

University Hospitals Cleveland Medical Center

Clinical Trials Leland Metheny, MD is currently running

Image of trial facility.

Inotuzumab Ozogamicin Post-Transplant

for Leukemia and Lymphoma

This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin is considered experimental in this study.

Recruiting

1 award

Phase 1 & 2

Image of trial facility.

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.

Recruiting

2 awards

Phase 3

32 criteria

More about Leland Metheny, MD

Clinical Trial Related

9 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 6 Active Clinical Trials

Treatments Leland Metheny, MD has experience with

  • Lenalidomide
  • Carmustine
  • Filgrastim
  • O6-benzylguanine
  • P140K-MGMT
  • Photon Based Radiotherapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Leland Metheny, MD specialize in?

Is Leland Metheny, MD currently recruiting for clinical trials?

Are there any treatments that Leland Metheny, MD has studied deeply?

What is the best way to schedule an appointment with Leland Metheny, MD?

What is the office address of Leland Metheny, MD?

Is there any support for travel costs?